Key Takeaways:
The real bull market in managed care is here. Jim Cramer used his July 9 CNBC Stop Trading segment to declare health insurance the market's best-kept winner, framing CVS Health as the prime beneficiary of a retail pharmacy shakeout that has left Walgreens and Rite Aid "basically disappearing."
"The real bull market here has been for the last month the UNH managed care insurance business," Cramer said. He added that "the price increases in DRAM and price increases in health insurance are going to be double-digit," pointing to a pricing cycle that is finally rewarding underwriters for the risks they carry.
The numbers back the call. CVS Health posted adjusted EPS of $2.57 in Q1 2026, beating the $2.21 consensus, on revenue of $100.43 billion. Its Aetna-anchored Health Care Benefits segment delivered operating income of $3.04 billion, up 52.6% year over year, as the medical benefit ratio improved to 84.6% from 87.3%. Management raised full-year adjusted EPS guidance to a range of $7.30 to $7.50 and lifted the operating cash flow target to at least $9.5 billion. CVS shares have gained 61.69% over the past year, trading near $104.72, with 24 buy ratings against four holds.
The thesis extends beyond CVS. UnitedHealth Group reported Q1 adjusted EPS of $7.23 versus a $6.61 consensus, with the medical cost ratio improving 90 basis points to 83.9%. Management explicitly cited "repricing across all lines of business in response to elevated but in-line cost trends" as the driver of margin expansion. The company is willingly shrinking — guiding for UnitedHealthcare enrollment of 46.9 million to 47.5 million, down from 49.8 million in 2025 — as it exits unprofitable contracts. Full-year adjusted EPS guidance was raised to greater than $18.25. Polymarket traders price a 71% probability that UNH beats its next quarterly report, due July 16.
Humana has delivered the strongest share price performance among the three. Q1 2026 revenue jumped 23.5% year over year to $39.65 billion, with individual Medicare Advantage membership rising roughly 1.14 million, or 22% year to date. The insurance segment benefit ratio landed at 89.4%, favorable to internal guidance. Shares are up 55.89% year to date, leading the managed care group.
The improved CMS benchmark funding and IRA-driven Part D subsidies have shifted the Medicare Advantage outlook. Humana's FY2026 adjusted EPS guidance of at least $9.00 steps down from the prior year's $17.14, reflecting the bonus-payment reset tied to Star Ratings cuts. Cramer's argument is that the regulatory environment is moving toward equilibrium faster than bears expect.
Cramer's thesis rests on pricing power returning to an industry that spent years absorbing higher medical costs without commensurate premium increases. With Walgreens shrinking its pharmacy footprint and Rite Aid restructuring, CVS captures more front-of-store traffic and prescription volume that flows directly into its vertically integrated insurance and pharmacy benefit engine.
The next catalyst arrives July 16 with UnitedHealth's earnings, followed by reports from CVS and Humana later in the quarter. Investors will watch whether improving medical cost ratios and higher premiums continue translating into stronger margins across the sector. If Cramer's double-digit pricing thesis holds, the managed care group may still have room to run despite the year-to-date gains.
This article is for informational purposes only and does not constitute investment advice.
